Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PIM1
REST API REST API
Homo sapiens
PIM1 is differentially expressed in 300 experiments: 137 organism parts: bone marrow, placenta, ... (135 more);, 187 disease states: normal, chronic myelogenous leukemia, ... (185 more);, 92 cell types 413 cell lines 57 compound treatments and 67 other conditions.
Synonyms PIM
Orthologs Pim1 (Mus musculus)   pim1 (Danio rerio)   ENSCING00000007955 (Ciona intestinalis)   Pim1 (Rattus norvegicus)   PIM1 (Gallus gallus)   PIM1_BOVIN (Bos taurus)   PIM1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, phosphotransferase activity, alcohol group as acceptor, cytoplasm, cell proliferation, membrane, negative regulation of apoptosis, metal ion binding, protein tyrosine kinase activity, transcription factor binding, ATP binding, cell cycle, multicellular organismal development, nucleus, manganese ion binding, nucleotide binding, protein serine/threonine kinase activity, lipopolysaccharide biosynthetic process, protein kinase activity, positive regulation of cyclin-dependent protein kinase activity involved in G1/S, protein autophosphorylation, protein phosphorylation, negative regulation of sequence-specific DNA binding transcription factor activity
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom, LipoPS_kinase
UniProt Accession P11309
Search EB-eye ENSG00000137193
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-18105, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-4717, E-GEOD-2450, ... (41 experiments)

Factor Value U/D Experiments
HL-60
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
K562
3
E-MTAB-37, E-GEOD-96, E-GEOD-24147
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
BT474
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
Raji
2
E-MTAB-37, E-GEOD-96
407 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-3920, E-MEXP-750, E-MEXP-66, E-GEOD-360, ... (44 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-6740, E-TABM-145
human embryonic stem cell
2
E-GEOD-18147, E-GEOD-18265
centroblast
2
E-TABM-702, E-GEOD-15271
testis - germ cell
2
E-AFMX-5, E-TABM-145
testis - leydig cell
2
E-AFMX-5, E-TABM-145
endothelial cell
1
2
E-GEOD-19240, E-GEOD-96, E-GEOD-3920
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MTAB-62, E-GEOD-5418, ... (58 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-6014, E-GEOD-4290, E-GEOD-4412, E-MTAB-62
chronic myelogenous leukemia
1
3
E-MTAB-37, E-GEOD-96, E-MTAB-62, E-GEOD-5550
multiple myeloma
2
E-MTAB-62, E-GEOD-2113
prostate carcinoma
2
E-MTAB-62, E-GEOD-96
head and neck squamous cell carcinoma
1
2
E-GEOD-6631, E-MTAB-62, E-GEOD-2379
acute lymphoblastic leukemia
1
2
E-MTAB-62, E-GEOD-96, E-MTAB-37
181 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-5258, E-TABM-782, E-GEOD-697, E-GEOD-5824, ... (38 experiments)

Factor Value U/D Experiments
interferon-gamma
2
E-GEOD-1432, E-GEOD-1925
endotoxin
1
E-GEOD-3026
saline
1
E-GEOD-3026
hemin
1
E-GEOD-1036
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
E-GEOD-6932
M-CSF
1
E-GEOD-5099
51 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22544, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-21750, E-GEOD-22593, E-GEOD-2292, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-12773, E-MEXP-1446, ... (12 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-16363, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-980, E-GEOD-6802, E-GEOD-512 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-7114, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.413 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM